|1.||Boh, Bojana: 2 articles (10/2008 - 06/2003)|
|2.||Berovic, Marin: 2 articles (10/2008 - 06/2003)|
|3.||Wraber, Branka: 2 articles (10/2008 - 06/2003)|
|4.||Svagelj, Mirjan: 1 article (10/2008)|
|5.||Menard, Anja: 1 article (10/2008)|
|6.||Simcic, Sasa: 1 article (10/2008)|
|7.||Zore, Irena: 1 article (06/2003)|
|8.||Habijanic, Jozica: 1 article (06/2003)|
|9.||Hodzar, Damjan: 1 article (06/2003)|
|10.||Pohleven, Franc: 1 article (06/2003)|
07/01/1988 - "A comparative study of parent MDP and MDP-Lys(L18) in relation to the protection against infection with various pathogens revealed the same spectrum of antiinfectious activity, but a different potency: the greater strength of MDP-Lys(L18) was demonstrated both by the smaller influence of bacterial inoculum size on its activity and by the smaller minimal dosage required for inducing significant activity. "
08/01/1996 - "Romurtide given orally enhanced the nonspecific resistance against microbial infections and hematopoiesis up to the levels achieved by subcutaneous (s.c.) injection of the compound in mice. "
04/01/1996 - "Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus."
10/01/1995 - "The effect of MDP-Lys(L18) was also restorative when given to the mice 4 or 7 days after infection. "
10/01/1995 - "Mice given 100 micrograms/mouse of MDP-Lys(L18) before infection exhibited significantly higher survival rates than those of non-treated mice. "
01/01/1989 - "In this study, the usefulness of muroctasin in leukopenia was suggested when administered at dosages of 200 micrograms for 6 days."
11/01/1988 - "In the present study, the usefulness of muroctasin in leukopenia was indicated when administered at dosages of 200 micrograms for 6 days."
06/01/1994 - "The effectiveness of thrice-weekly injection of Romurutide for leukocytopenia due to radiation therapy was analyzed. "
06/01/1994 - "[Effectiveness of thrice-weekly injection of romurutide for prophylaxis of leukocytopenia during radiation therapy]."
07/01/1988 - "Restorative activity of muroctasin on leukopenia associated with anticancer treatment."
07/01/1988 - "The results of this study indicate that MDP-Lys(L18) is useful in improving the WBC count in leukopenic cancer patients treated with anticancer therapy. "
02/01/1998 - "Romurtide is applied in cancer patients for the recovery of the number and functions of monocytes, neutrophils and platelets. "
04/01/1992 - "It was also shown that the clinical effectiveness of romurtide on the restoration of the number of leukocytes and platelets of cancer patients treated with chemotherapy or radiation therapy. "
07/01/1988 - "MDP-Lys(L18) was considerably more effective in patients with solid tumors than in those with hematological malignancies. "
02/01/1994 - "These results suggest that MDP-Lys(L18) is able to enhance host resistance to reduce tumour metastasis and is a potent immunomodulating agent which may be applied prophylactically or therapeutically for the treatment of cancer metastasis."
10/01/1996 - "These results demonstrated a possible therapeutic potential of romurtide in the management of thrombocytopenia associated with myelosuppression."
10/01/1996 - "Romurtide given subcutaneously elevated significantly the peripheral platelet counts during both early initiation and later recovery phase of thrombocytopenia, thereby shortening the time required for recovery to a normal platelet level and the duration of thrombocytopenia. "
05/01/1994 - "These results indicate a possible therapeutic potential of romurtide in the management of thrombocytopenia associated with myelosuppression."
05/01/1994 - "In the irradiated animals, the treatment with romurtide increased platelet counts during the recovery phase of thrombocytopenia, thus apparently decreasing the time required for recovery to a normal platelet level. "
08/01/1989 - "Activation of the cytokine network by muroctasin as a remedy for leukopenia and thrombopenia."
02/01/1994 - "MDP-Lys(L18) was also effective in the inhibition of liver metastasis of L5178Y-ML25 lymphoma cells by administration 2 or 4 days before tumour inoculation. "
10/01/1988 - "Hematological response to the new synthetic muramyl dipeptide derivative muroctasin after chemotherapy in patients with malignant lymphoma. "
02/01/1994 - "The antimetastatic effects of MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide (MDP), against three different types of highly metastatic murine tumour cells, B16-BL6 melanoma, colon 26-M3.1 carcinoma and L5178Y-ML25 T lymphoma, were examined in C57BL/6, Balb/c and CDF1 mice, respectively. "
|2.||Granulocyte Colony-Stimulating Factor (G-CSF)
|4.||Interleukin-1beta (Interleukin 1 beta)
|5.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|6.||Anti-Bacterial Agents (Antibiotics)
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|9.||Conditioned Culture Media
|10.||Interleukin-1 (Interleukin 1)
|1.||Drug Therapy (Chemotherapy)